Paediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies. Open. In Development. In Development. Open. Open.

Similar documents
Paediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies

National Cancer Drugs Fund List - Approved

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

Open / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )

CRCTU staff congratulate Pam on her promotion to Professor

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

SUPPLEMENTARY INFORMATION

Chemotherapy Treatment Algorithms for Urology Cancer

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

CLINICAL TRIALS ACC. Jul 2016

Title Cancer Drug Phase Status

CLIC Sargent Eligibility Criteria

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013

Performance in Initiating Clinical Research Q4 2015/16

Performance in Initiating Clinical Research Q2 2016/17

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

PEDIATRIC. BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a COMPANION STUDIES

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

CancerPACT Cancer Patients Alliance for Clinical Trials

Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date

For Health Professionals Who Care For Cancer Patients

MEDICAL PRIOR AUTHORIZATION

Performance in Initiating Clinical Research

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Macmillan Publications

National Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008

Diagnosis Place of delivery Proforma

1. Background & Scope 3

TUESDAY, 18th OCTOBER, 2016 / DAY -2

Comprehensive Cancer Cover

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Open Trials as of end of March 2016

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Radiation Oncology MOC Study Guide

Index. Note: Page numbers of article titles are in boldface type.

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Advances in haematological malignancies focus on lymphoid disease

CHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling

OPEN TRIALS Accruals counted until 30-April Current Accrual

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

National Cancer Drugs Fund List Ver4.4

National Cancer Drugs Fund List Ver4.0

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Our Clinical Trials. Oncology

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship

National Cancer Drugs Fund List

Summary of Research and Writing Activities in Oncology

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)

Proceedings of Congress

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Notification to Implement Issued by pcodr: December 14, 2012

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Product Visual Guide

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

UNIVERSITY HOSPITAL OF HERAKLION DEPARTMENT OF HAEMATOLOGY

Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER

Open clinical uro-oncology trials in Canada

Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Recommended Timing for Transplant Consultation

For Health Professionals Who Care For Cancer Patients

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

Radiation Oncology Study Guide

The Clinical Research E-News

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

An D. Nguyen, MD Curriculum Vitae

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

Biological Therapies for Cancer: Questions and Answers

Studies proceeding under pre HRA-Approval system (NHS Permission)

Open clinical uro-oncology trials in Canada

Lynparza. Lynparza (olaparib) Description

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

An Overview. Paediatric Oncology. In Malawi

The Clinical Research E-News

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Bendamustine for relapsed follicular lymphoma refractory to rituximab

incidence rate x 100,000/year

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Transcription:

Paediatric Cancer Brain LGG2: Cooperative multicenter study for children and adolescents with Low Grade Glioma GD2: A Phase I/II dose schdule finding study of CH14.18/CHO continuous infusion combined wugt subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. LGG2@trials.bham.ac.uk GD2@trials.bham.ac.uk Germ Cell SIOP CNS GCT II: Prospective trial for the diagnosis and treatment of children, adolescents and young adults with intracranial germ cell tumours can-crctu-cctt@adf.bham.ac.uk Embryonic Tumour HRNBL: High risk neuroblastoma study 1 of SIOP- Europe (SIOPEN) hrnbl@trials.bham.ac.uk Haematology Malignancies Interfant 06: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia (LK 2006 10) EuroNet PHL C-1: First International Inter-Group Study for Classical Hodgkin s Lymphoma in Children and Adolescents UKALL 2011: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011 EuroNet PHL LP1: First international Inter-Group Study for nodular lymphocyte-predominant Hodgkin s Lymphoma in Children and Adolescents Inter-B-NHL 2010: Intergroup trial for children or adolescents with B-Cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients interfant06@trials.bham.ac.uk euronetphl@trials.bham.ac.uk ukall2011@trials.bham.ac.uk can-crctu-cctt@adf.bham.ac.uk interbnhl@trials.bham.ac.uk

Liver SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma siopel6@trials.bham.ac.uk Renal SIOP WILMS: SIOP nephroblastoma (wilms tumour) clinical trial and study siopwilms@trials.bham.ac.uk Sarcoma RMS 2005: A protocol for non metastatic rhabdomyosarcoma (STS 2006 04) EE99: EUROpean Ewing tumour working initiative of national groups. Ewing tumour studies 1999 VIT0910: International randomised phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in patients with refractory or relapsed Rhabdomyosarcoma rms2005@trials.bham.ac.uk EE99@trials.bham.ac.uk VIT0910@trials.bham.ac.uk Adult Cancer Bladder HYMN: A randomised controlled Phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guérin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy HYMN@trials.bham.ac.uk TUXEDO: Phase I/II feasibility study of cetuximab with cisplatin or 5FU and Mitomycin C with concurrent radiotherapy in muscle invasive bladder cancer Brain can-crctu-teama@adf.bham.ac.uk BPA: A Cancer Research UK pharmacokenetic study of p- boronophenylalanine (BPA) in patients with high glioma of optimise uptake parameters for clinical trials of boron neutron capture therapy can-crctu-edd@adf.bham.ac.uk Breast NEO-EXCEL: Neoadjuvant trial of pre-operative exemestane or neoexcel@trials.bham.ac.uk letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer

Haematology Malignancies RICAZA: Phase II study of the tolerability of adjunctive Azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for Acute Myeloid Leukaemia TRICE: Phase I/II study of the adjunctive use of Nilotinib in patients undergoing reduced intensity allogeneic transplantation for Imatinib resistant or intolerant Chronic Myeloid Leukaemia val/aza: Phase II study of the tolerability and efficacy of the histone deacetylase inhibitor sodium valproate administered in conjunction with 5-azacitidine, ATRA (all trans retinoic acid) and theophylline in patients with Acute Myeloid Leukaemia and high risk MDS ricaza@trials.bham.ac.uk trice@trials.bham.ac.uk valaza@trials.bham.ac.uk PICLLe: Phase I/II clinical trial to assess the efficacy and safety piclle@trials.bham.ac.uk of olaparib, a PARP-inhibitor, in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T- prolymphocytic leukaemia and mantle cell lymphoma LenaRIC: Phase II study of the adjunctive use of lenalidomide lenaric@trials.bham.ac.uk in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma MAJIC: A phase II study of Ruxolitinib (INCB424) in patients with High Risk Polycythaemia Vera or Essential Thrombocythaemia resistant to or intolerant of standard therapy BaP Pilot: Single Arm Phase II trial assessing the efficacy, compliance and safety of Bezafibrate and medroxyprogesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers. DeIron: A phase II study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes HA-1: A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mhag) HA-1 using a DNA and MVA prime/boost regimen RAvVA: A Randomised Phase II Trial of 5-Azacitidine versus Vorinostat in Combination with 5-Azacitidine in patients with Relapsed Acute Myeloid Leukaemia for Salvage Chemotherapy MAJIC@trials.bham.ac.uk De-iron@trials.bham.ac.uk HA1@trials.bham.ac.uk can-crctuhaematology@adf.bham.ac.uk can-crctuhaematology@adf.bham.ac.uk Head and Neck ArChIMEDEs Op: Accelerated Hypofractionation, Chemotherapy, Intensity Modulation and Evaluation of Dose Escalation in Oropharyngeal Cancer can-crctu-teamb@adf.bham.ac.uk

Hepatocellular Carcinoma BILCAP: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer TACE-2: A randomised placebo-controlled, double-blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer Homing of DCs: A clinical study of the homing of mature autologous dendritic cells in vivo in patients with hepatocellular carcinoma or liver metastases. bilcap@trials.bham.ac.uk TACE2@trials.bham.ac.uk can-crctu-edd@adf.bham.ac.uk Lung STOMP: A randomised phase II study of AZD2281 maintenance treatment in patients with chemosensitive small cell lung cancer STOMP@trials.bham.ac.uk 3D-i: A dose-finding study of combination chemotherapy with can-crctu-edd@adf.bham.ac.uk cisplatin, pemetrexed and docetaxel in the first line treatment of advanced non-squamous non small cell lung cancer. NOURISH P2: Improving the management of cachexia in Nourish@trials.bham.ac.uk patients with advanced lung cancer: Does the introduction of beta-hydroxy-beta-methylbutyrate supplementation improve nutritional status and quality of life? Mixed Primary NOURISH Pilot 1: A pilot study to determine changes in lean body mass in people with cancer. Nourish@trials.bham.ac.uk Prostate Trapeze: A randomised phase II/III study of docetaxel plus prednisolone vs docetaxel plus prednisolone plus zoledronic acid vs docetaxel plus prednisolone plus strontium-89 vs docetaxel plus prednisolone plus zoledronic acid plus strontium-89 in hormone refractory prostate cancer metastatic to bone trapeze@bham.ac.uk AdUP: A phase 1 clinical trial of a replication defective Ad5 vector expressing nitroreductase and GMCSF (AdNRGM) given via brachytherapy, followed by CB1954, in patients with locally relapsed prostate cancer Alpharadin: Alpharadin and docetaxel randomised phase II trial to assess the feasibility and safety of the combination of docetaxel plus Ra-223 (Alpharadin) in the first line chemotherapy treatment of men with bony metastatic castrate resistant prostate cancer can-crctu-edd@adf.bham.ac.uk can-crctu-teama@adf.bham.ac.uk

Renal PAZ02: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and Performance Status 2 (ECOG) Sarcoma can-crctu-teama@adf.bham.ac.uk Vortex: Randomised trial of dose and volume of post-operative radiotherapy given to adult patients with extremity soft tissue sarcoma Axi-STS: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas SCART: Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi s sarcoma (KS). vortex@trials.bham.ac.uk Axi-STS@trials.bham.ac.uk scart@trials.bham.ac.uk Skin UKMCC-01: A phase II study of pazopanib in metastatic merkel can-crctu-teamb@adf.bham.ac.uk cell carcinoma SPOT: Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments (SPOT): a feasibility study Ovary can-crctu-teamb@adf.bham.ac.uk DESKTOP III: A randomized multicenter study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer DESKTOPIII@trials.bham.ac.uk

Adult Non-Cancer Liver LEAN: A 48-week phase II, randomised, double blinded placebo controlled, parallel-group, multi centre trial on Liraglutide s safety, efficacy and action on liver histology and mechanism in overweight patients with non-alcoholic steatohepatitis, with or without type II diabetes REALISTIC: A multicentre, phase II, open label, randomised controlled trial of repeated autologous infusions of g-csf mobilised CD133+ bone marrow stem cells in patients with cirrhosis ITX5061: Phase I study of Hepatitis C Virus (HCV) entry inhibitor (ITX5061) in liver transplant recipients with HCV infection lean@trials.bham.ac.uk Realistic@trials.bham.ac.uk ITX5061@trials.bham.ac.uk IMMUNOTACE: A phase II randomised clinical trial of Immunotace@trials.bham.ac.uk conditioning cyclophosphamide and chemoembolisation with or without vaccination with Dendritic Cells pulsed with HepG2 lysate in vivo in patients with Hepatocellular Carcinoma